Trials / Recruiting
RecruitingNCT06725758
A Phase 1/2, First-in-Human Study On ODM-212 In Subjects With Selected Advanced Solid Tumours
- Status
- Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 315 (estimated)
- Sponsor
- Orion Corporation, Orion Pharma · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Multi-site, open-label, first-in-human study with 2 parts (dose escalation and dose expansion) in subjects with selected advanced solid tumours
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ODM-212 | ODM-212 5mg and/or 40mg tablets |
Timeline
- Start date
- 2023-10-26
- Primary completion
- 2027-12-31
- Completion
- 2027-12-31
- First posted
- 2024-12-10
- Last updated
- 2026-01-15
Locations
1 site across 1 country: United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06725758. Inclusion in this directory is not an endorsement.